CAR-T cell therapy has transformed the treatment landscape for certain blood cancers. The approach involves harvesting a patient’s own T cells, genetically engineering them to express a synthetic receptor that recognizes CD19, a protein found on the surface of most B cell malignancies, and reinfusing them after lymphodepleting chemotherapy. Despite dramatic remission rates in clinical trials, the therapy does not work for everyone, and even among initial responders, relapse remains common. Immunologists have attributed this heterogeneity to factors such as tumor burden, prior treatment lines, T cell fitness, and the immunosuppressive tumor microenvironment. The new study adds a previously underappreciated variable to that list: the metabolic products of drug-resistant bacteria colonizing the gut and other mucosal surfaces.

Carbapenem-resistant Klebsiella pneumoniae, or CRKP, is one of the most feared pathogens in modern hospitals, classified by the World Health Organization as a critical-priority pathogen for which new treatments are urgently needed. Patients with hematologic malignancies who have undergone intensive chemotherapy, stem cell transplantation, or prolonged antibiotic exposure are particularly susceptible to CRKP colonization, in which the bacterium establishes itself in the body without necessarily causing an overt bloodstream infection. The research team, led by corresponding authors Xiaojian Zhu and Yi Xiao, focused on 1,5-pentanediamine, a diamine metabolite produced by several members of the Enterobacteriaceae family, including Klebsiella species, through the decarboxylation of lysine.

Using liquid chromatography–tandem mass spectrometry, an analytical technique capable of detecting and quantifying small molecules with high sensitivity and specificity, the researchers measured serum PDA concentrations in 30 CRKP-colonized hematology patients who had no documented bloodstream infection at the time of sampling. The metabolite was detectable in the serum of all 30 patients. The authors are careful to note an important caveat: because the study lacked a non-colonized comparator cohort, these findings demonstrate that PDA is present in the circulation of colonized patients but do not prove that CRKP is the exclusive source of the metabolite.

With detectable PDA levels established in the clinical population, the team turned to the central question of the study: what happens to CAR-T cells when they are exposed to this metabolite? Healthy-donor-derived CD19 CAR-T cells were cultured with PDA at concentrations ranging from 0 to 12 millimolar, with 9 millimolar used for most functional assays. These millimolar concentrations reflect the acute exposure levels achievable in vitro and are considerably higher than the trace serum levels measured in patients, a point the researchers acknowledge when discussing the physiological relevance of their findings.

The results were striking. PDA exposure reduced the metabolic activity of CAR-T cells, as measured by assays of cellular respiration and energy production, and increased apoptosis, the programmed cell death pathway that determines how long engineered T cells survive in circulation. Since CAR-T persistence correlates strongly with durable clinical responses, any insult that shortens the lifespan of these cells could directly undermine therapeutic efficacy. Beyond survival, PDA-treated cells showed a shift in their immunological identity. The metabolite upregulated both activation markers and checkpoint-associated inhibitory molecules—the same brakes that tumors exploit to disable T cells—and altered the balance between CD4 helper and CD8 cytotoxic subsets. Most tellingly, the proportion of regulatory T cells, an immunosuppressive population that dampens antitumor immunity, increased in the presence of PDA.

Functional testing reinforced the picture of a compromised therapeutic product. When PDA-treated CAR-T cells were confronted with NALM-6 cells, a well-established B cell leukemia line used as a standard CD19-positive target, their killing capacity dropped significantly. The cells also produced lower amounts of inflammatory cytokines such as interferon-gamma, which recruits and activates other arms of the immune system, and released reduced levels of perforin and granzyme B, the cytotoxic molecules that CAR-T cells use to punch holes in tumor cells and trigger their self-destruction. Intriguingly, one measure of immune engagement was spared: CD107a degranulation, a marker of the physical process by which T cells release their toxic granules, remained intact. This dissociation—cells that can still fire their weapons but do so with less lethality and less inflammatory support—suggests that PDA does not simply shut CAR-T cells down but pushes them into a subtle, dysfunctional state.

To understand the molecular basis of this dysfunction, the researchers performed RNA sequencing on PDA-exposed CAR-T cells, a technique that catalogs the activity of thousands of genes simultaneously. The transcriptomic profiles revealed enrichment of pathways governing the cell cycle, apoptosis, and stress responses, alongside a suppression of immune signaling pathways. The gene-expression signature bore hallmarks of T cell exhaustion, the hypo-responsive state familiar from chronic viral infections and tumors. Quantitative reverse-transcription PCR confirmed key transcriptional changes at the individual gene level.

One of the most clinically consequential findings involved immune checkpoint blockade. Because PDA upregulated checkpoint-associated inhibitory markers, the researchers tested whether blocking PD-1, the receptor targeted by some of the most widely used cancer immunotherapies, could rescue the metabolite-impaired cells. Under the conditions tested, PD-1 blockade alone failed to restore CAR-T function. This result implies that the damage inflicted by the metabolite extends beyond a single checkpoint axis and may involve broader metabolic and transcriptional reprogramming that checkpoint inhibitors cannot readily reverse.

The authors are explicit about the limitations of their work. The experiments relied on acute exposure of healthy-donor-derived CAR-T cells to millimolar PDA concentrations in vitro, whereas patients are likely exposed to lower metabolite levels over longer periods, in a body shaped by infection, inflammation, and prior therapies. Serum PDA was measured in only a single cohort without controls, and the killing assays used a single target-cell line. Validation in chronic low-dose exposure models, controlled clinical cohorts comparing colonized and non-colonized patients, patient-derived CAR-T cells, and additional tumor targets will be essential before these findings can inform clinical practice.

Even with those caveats, the study opens an unexpected frontier at the intersection of microbiology, metabolism, and cellular immunotherapy. If drug-resistant bacterial colonization can chemically undermine engineered immune cells, then screening patients for CRKP colonization, quantifying bacterial metabolites before cell infusion, or intervening with decolonization strategies, adsorbents, or metabolic inhibitors might one day become part of standard CAR-T preparation. The work also carries broader implications for the growing recognition that microbiota-derived metabolites—molecules once dismissed as inert waste products of bacterial metabolism—can act as systemic immunomodulators with the power to shape the success or failure of cutting-edge cancer treatments.

The finding places microbial metabolism at the center of antiviral biology. Viruses depend on host cells for nearly every stage of their life cycle, including entry, genome replication, protein production and the assembly of new viral particles. At the same time, host cells continuously monitor their surroundings for signs of infection and adjust their metabolism, gene activity and immune signaling accordingly. Metabolites produced by bacteria can affect these processes by acting as signaling molecules, altering cellular enzymes or changing the chemical environment in which infection takes place. The study suggests that one such molecule, generated from tryptophan by commensal bacteria, can interfere with viral infection through mechanisms that connect the microbiome to intracellular antiviral defenses.

Tryptophan metabolism is particularly important because it sits at the intersection of nutrition, immunity and cellular communication. In mammals, tryptophan can be processed through several biochemical routes, generating compounds that influence inflammatory signaling, barrier tissues and the activity of immune cells. Bacteria possess their own enzymatic pathways for transforming the amino acid, and the products of those reactions may reach nearby epithelial cells or circulate to more distant organs. By identifying a tryptophan-derived bacterial metabolite with antiviral activity, the researchers highlight how a dietary nutrient can be converted by the microbiome into a molecule capable of changing the outcome of viral exposure.

The biological significance of the result lies in its focus on commensal organisms rather than classical pathogens or laboratory-engineered probiotic strains. Commensal bacteria are members of the microbial communities that inhabit sites such as the intestine, airways and skin without normally causing disease. Their influence is often indirect: they compete with harmful microbes, strengthen physical barriers and educate immune cells. The findings described in the study suggest an additional role, in which bacterial chemistry directly modifies the susceptibility of host cells to viral infection. This expands the concept of colonization resistance, traditionally associated with protection against competing bacteria, to include a degree of resistance against viruses.

For a virus, the presence of an antiviral metabolite could affect infection at several points. A molecule may make host cells less permissive to viral entry, interfere with the cellular machinery required for genome replication or promote the expression of antiviral genes. It may also influence the balance between protective inflammation and tissue-damaging immune activation. The precise route depends on the chemical identity of the metabolite and the virus being studied, but the general principle is important: microbial products can act before, during or after infection to reshape the cellular environment on which a virus relies. Rather than attacking viral particles directly like a conventional antiviral drug, the metabolite may work by preparing the host cell to respond more effectively.

This distinction could prove valuable in antiviral research. Many antiviral medicines are designed against specific viral enzymes or structural proteins, making them highly effective in some infections but less useful when viruses evolve resistance or when a new virus emerges. A host-directed mechanism based on a microbial metabolite might target cellular pathways that viruses cannot easily change without compromising their own replication. It could therefore offer activity across related viruses, although such breadth would need to be demonstrated experimentally. Host-directed strategies also require careful evaluation, because the same pathways that limit viral replication can influence inflammation, metabolism and other physiological processes.

The study also raises questions about why individuals may differ in their vulnerability to infection. Microbiome composition varies widely between people and can be altered by diet, age, medication, illness, geography and immune status. Two individuals exposed to the same virus may therefore carry different populations of bacteria, with different capacities to produce antiviral metabolites. Antibiotics or disruptions to the intestinal community could potentially reduce the availability of protective compounds, while dietary patterns or targeted microbial interventions might increase it. These possibilities remain to be tested, but they provide a biological framework for understanding how the microbiome could contribute to variation in viral disease without replacing the established roles of vaccination, immune memory and direct antiviral treatment.

Translating the discovery into a medical intervention will require several stages of research. Scientists will need to determine how much of the metabolite is produced in humans, where it accumulates, how long it persists and whether its concentrations change during infection. They must also establish whether protection depends on a particular bacterial species, a broader microbial community or a defined combination of organisms. The safety profile will be equally important. A compound that suppresses viral replication in cultured cells may behave differently in living tissues, where metabolism, transport and immune responses can alter its effects. Clinical studies will be needed to establish whether manipulating this pathway can prevent infection, reduce disease severity or improve recovery.

For now, the work offers a significant conceptual advance in viral science: the body’s microbial residents can contribute to antiviral defense by transforming ordinary nutrients into biologically active signals. It presents the microbiome as a biochemical partner in host protection, not simply as a collection of organisms competing for space. As researchers continue to map the molecules produced by commensal bacteria, similar pathways may emerge linking microbial metabolism to resistance against a range of viral diseases. The discovery does not suggest that a single metabolite can replace existing public-health measures, but it points toward a future in which antiviral strategies may combine direct drugs with therapies designed to support the chemical defenses generated by the microbiome.

Subject of Research: The role of commensal bacteria and a tryptophan-derived metabolite in inhibiting viral infections.

Article Title: Commensal bacteria inhibit viral infections via a tryptophan metabolite.

Article References: Jiang, D., Soo, N., Tan, C.Y. et al. “Commensal bacteria inhibit viral infections via a tryptophan metabolite.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76412-8

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76412-8

Keywords: commensal bacteria, microbiome, viral infections, antiviral defense, tryptophan metabolite, microbial metabolism, host–microbe interactions, viral science